Intranasal rifampicin for Alzheimer's disease prevention

INTRODUCTION: Oral rifampicin has been shown to significantly reduce amyloid β (Aβ) and tau pathologies in mice. However, it shows occasional adverse effects such as liver injury in humans, making its use difficult for a long period. METHODS: To explore safer rifampicin treatment, APP(OSK) mice, a m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Alzheimers Dement (N Y)
Main Authors: Umeda, Tomohiro, Tanaka, Akiko, Sakai, Ayumi, Yamamoto, Akira, Sakane, Toshiyasu, Tomiyama, Takami
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2018
Assuntos:
Featured Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6076366/
https://ncbi.nlm.nih.gov/pubmed/30094330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2018.06.012
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares